vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and VIEMED HEALTHCARE, INC. (VMD). Click either name above to swap in a different company.
VIEMED HEALTHCARE, INC. is the larger business by last-quarter revenue ($76.2M vs $75.5M, roughly 1.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 25.5%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $9.7M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 22.7%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Viemed Healthcare, Inc. is a medical technology firm specializing in respiratory care solutions. It develops, manufactures and distributes portable ventilators, respiratory therapy devices and related support services, catering to acute care, post-acute care and home care segments across North America, Europe and key Asia-Pacific markets for patients with respiratory conditions.
PBYI vs VMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $76.2M |
| Net Profit | — | $5.6M |
| Gross Margin | 69.3% | 57.9% |
| Operating Margin | 22.7% | 11.0% |
| Net Margin | — | 7.4% |
| Revenue YoY | 27.7% | 25.5% |
| Net Profit YoY | — | 30.7% |
| EPS (diluted) | $0.26 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $76.2M | ||
| Q3 25 | $54.5M | $71.9M | ||
| Q2 25 | $52.4M | $63.1M | ||
| Q1 25 | $46.0M | $59.1M | ||
| Q4 24 | $59.1M | $60.7M | ||
| Q3 24 | $80.5M | $58.0M | ||
| Q2 24 | $47.1M | $55.0M | ||
| Q1 24 | $43.8M | $50.6M |
| Q4 25 | — | $5.6M | ||
| Q3 25 | $8.8M | $3.5M | ||
| Q2 25 | $5.9M | $3.2M | ||
| Q1 25 | $3.0M | $2.6M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $20.3M | $3.9M | ||
| Q2 24 | $-4.5M | $1.5M | ||
| Q1 24 | $-4.8M | $1.6M |
| Q4 25 | 69.3% | 57.9% | ||
| Q3 25 | 77.7% | 57.5% | ||
| Q2 25 | 76.5% | 58.3% | ||
| Q1 25 | 77.1% | 56.3% | ||
| Q4 24 | 76.4% | 59.5% | ||
| Q3 24 | 63.9% | 59.3% | ||
| Q2 24 | 77.4% | 59.8% | ||
| Q1 24 | 75.5% | 58.9% |
| Q4 25 | 22.7% | 11.0% | ||
| Q3 25 | 17.6% | 7.8% | ||
| Q2 25 | 12.7% | 8.1% | ||
| Q1 25 | 8.7% | 6.5% | ||
| Q4 24 | 22.6% | 10.6% | ||
| Q3 24 | 27.4% | 9.7% | ||
| Q2 24 | -4.6% | 6.6% | ||
| Q1 24 | -5.3% | 4.4% |
| Q4 25 | — | 7.4% | ||
| Q3 25 | 16.2% | 4.9% | ||
| Q2 25 | 11.2% | 5.0% | ||
| Q1 25 | 6.5% | 4.4% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | 25.2% | 6.7% | ||
| Q2 24 | -9.6% | 2.7% | ||
| Q1 24 | -11.0% | 3.2% |
| Q4 25 | $0.26 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.12 | $0.08 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.40 | $0.10 | ||
| Q3 24 | $0.41 | $0.10 | ||
| Q2 24 | $-0.09 | $0.04 | ||
| Q1 24 | $-0.10 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $13.5M |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $141.5M |
| Total Assets | $216.3M | $199.2M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | $13.5M | ||
| Q3 25 | $94.4M | $11.1M | ||
| Q2 25 | $96.0M | $20.0M | ||
| Q1 25 | $93.2M | $10.2M | ||
| Q4 24 | $101.0M | $17.5M | ||
| Q3 24 | $96.7M | $11.3M | ||
| Q2 24 | $96.8M | $8.8M | ||
| Q1 24 | $107.2M | $7.3M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
| Q4 25 | $130.3M | $141.5M | ||
| Q3 25 | $115.3M | $133.6M | ||
| Q2 25 | $104.7M | $139.7M | ||
| Q1 25 | $97.1M | $134.8M | ||
| Q4 24 | $92.1M | $131.4M | ||
| Q3 24 | $71.1M | $125.0M | ||
| Q2 24 | $48.5M | $119.4M | ||
| Q1 24 | $51.0M | $116.3M |
| Q4 25 | $216.3M | $199.2M | ||
| Q3 25 | $202.9M | $202.4M | ||
| Q2 25 | $194.9M | $184.6M | ||
| Q1 25 | $196.2M | $178.1M | ||
| Q4 24 | $213.3M | $177.1M | ||
| Q3 24 | $220.7M | $169.5M | ||
| Q2 24 | $205.0M | $163.9M | ||
| Q1 24 | $214.1M | $154.9M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $18.4M |
| Free Cash FlowOCF − Capex | $14.4M | $9.7M |
| FCF MarginFCF / Revenue | 19.1% | 12.7% |
| Capex IntensityCapex / Revenue | 0.0% | 11.5% |
| Cash ConversionOCF / Net Profit | — | 3.27× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $18.4M | ||
| Q3 25 | $9.7M | $18.4M | ||
| Q2 25 | $14.1M | $12.3M | ||
| Q1 25 | $3.6M | $2.9M | ||
| Q4 24 | $15.6M | $15.0M | ||
| Q3 24 | $11.0M | $12.7M | ||
| Q2 24 | $1.0M | $10.2M | ||
| Q1 24 | $11.2M | $1.2M |
| Q4 25 | $14.4M | $9.7M | ||
| Q3 25 | $9.7M | $10.7M | ||
| Q2 25 | $14.1M | $4.1M | ||
| Q1 25 | $3.6M | $-12.6M | ||
| Q4 24 | $15.6M | $3.2M | ||
| Q3 24 | $11.0M | $1.7M | ||
| Q2 24 | $1.0M | $1.2M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 17.7% | 14.9% | ||
| Q2 25 | 26.8% | 6.5% | ||
| Q1 25 | 7.7% | -21.4% | ||
| Q4 24 | 26.4% | 5.2% | ||
| Q3 24 | 13.7% | 3.0% | ||
| Q2 24 | 2.1% | 2.3% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | 0.0% | 11.5% | ||
| Q3 25 | 0.0% | 10.6% | ||
| Q2 25 | 0.0% | 12.9% | ||
| Q1 25 | 0.1% | 26.2% | ||
| Q4 24 | 0.0% | 19.5% | ||
| Q3 24 | 0.0% | 19.0% | ||
| Q2 24 | 0.0% | 16.3% | ||
| Q1 24 | 0.0% | 11.9% |
| Q4 25 | — | 3.27× | ||
| Q3 25 | 1.10× | 5.23× | ||
| Q2 25 | 2.41× | 3.88× | ||
| Q1 25 | 1.21× | 1.09× | ||
| Q4 24 | — | 3.47× | ||
| Q3 24 | 0.54× | 3.29× | ||
| Q2 24 | — | 6.94× | ||
| Q1 24 | — | 0.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
